Therapeutically, our work suggests that –SSH–Alb could be developed as a pharmacological H2S donor, applied in various conditions characterized by H2S deficiency, including cardiovascular diseases, neurodegeneration, and aging-related disorders [25,53]. The gene discussed is ALB; the disease is cardiovascular disorder.